Biotech RadarJobs updated

COMPANY

Antiva Biosciences

HQ: Redwood City, CA source · antivabio.com ↗

Clinical Phase 2

Antiva is developing topical therapies to treat pre-cancerous lesions caused by human papillomavirus (HPV). From company website Source · Oct 12, 2026

Keywords: HSIL, High Grade Squamous Intraepithelial Lesions Cervical Intraepithelial Neoplasia HSIL of Cervix High-Grade Cervical Intraepithelial Neoplasia Human Papilloma Virus Cervical Cancer Cervical Neoplasm Cervical Dysplasia Human Papilloma Virus Infection HIV Infection Anal Cancer Anus Neoplasm Human Papillomavirus Infection HIV Negative CIN - Cervical Intraepithelial Neoplasia High-Grade Squamous Intraepithelial Lesions ABI-1968 ABI-2280

Location: Redwood City, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

6Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts source ↗
  2. Trial start Phase 1/Phase 2: A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia source ↗
  3. Trial start Phase 1: Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. source ↗
  4. Trial start Phase 1: Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection source ↗
  5. Trial start Phase 1: Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection source ↗
  6. Trial start Phase 1: Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection source ↗

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06491446Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal InsertsPhase 1/Phase 2CompletedMar 27, 2024Oct 17, 2025 (actual)
NCT05502367A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial NeoplasiaPhase 1/Phase 2TerminatedSep 10, 2022Oct 27, 2025 (actual)
NCT03697226Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.Phase 1CompletedDec 21, 2018May 26, 2020 (actual)
NCT03677960Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) InfectionPhase 1TerminatedDec 17, 2018Jun 30, 2019 (actual)
NCT03239223Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) InfectionPhase 1CompletedJan 1, 2018Oct 30, 2018 (actual)
NCT03202992Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) InfectionPhase 1CompletedAug 11, 2017Feb 4, 2019 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback